Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare dosing compliance between study patients taking controlled release carvedilol once a day, and study patients taking immediate release carvedilol (Coreg) twice a day.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cardiovascular Clinical Studies
• Collaborator: GlaxoSmithKline
• Treatments: Carvedilol

Criteria

Inclusion Criteria:

• Ability to read English

• Stable symptoms of mild to severe heart failure

• Stable medical regimen for heart failure

• On a stable dose of Coreg for at least 2 months

• LVEF ≤40% within the previous 24 months

Exclusion Criteria:

• Uncorrected obstructive or regurgitant valve disease

• Complex congenital heart disease

• Recent ICD or pacemaker placement

• Recent coronary artery bypass surgery or stroke

• Candidate for heart transplanct within 5 months of study start

• Present or planned use of MAO inhibitors, alfpha-blockers, combined alpha-beta blockers, any Class I/II anti-arrythmnic agents, (amiodarone may be used if ≤ 200mg/day). Use of intravenous vasodilator/inotropic agents.